Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, & Martin DE. (2007). Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy, 51(10), 3574-3574. https://doi.org/10.1128/AAC.00152-07

SMITH PF, OGUNDELE A, FORREST A, WILTON J, SALZWEDEL K, DOTO J, ALLAWAY GP und MARTIN DE, 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial agents and chemotherapy. 1 Oktober 2007. Vol. 51, no. 10, p. 3574-3574. DOI 10.1128/AAC.00152-07.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, und Martin DE. „Phase I and II Study of the Safety, Virologic Effect, and pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3’,3’-dimethylsuccinyl)betulinic Acid (bevirimat) Against Human Immunodeficiency Virus Infection.“. Antimicrobial Agents and Chemotherapy, Bd. 51, Nr. 10, Oktober 2007, S. 3574-, https://doi.org/10.1128/AAC.00152-07.

Smith PF/Ogundele A/Forrest A/Wilton J/Salzwedel K/Doto J u. a.: Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection., Antimicrobial agents and chemotherapy 2007, 3574-3574.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP und Martin DE. (2007), „Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.“, Antimicrobial Agents and Chemotherapy, Vol. 51 No. 10, S. 3574-3574.